Phase II study of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first-line treatment in castration resistant prostate cancer (CRPC) patients (Pts)

被引：0
|
作者：
Fontana, A.
Bocci, G.
Galli, L.
Derosa, L.
Minuti, G.
D'Arcangelo, M.
Santini, D.
Landi, L.
Bursi, S.
Falcone, A.
机构：
[1] ASL6, Livorno, Italy
[2] Univ Pisa, ITT, Pisa, Italy
[3] ASL6, ITT, Livorno, Italy
[4] Univ Campus Bio Med, Rome, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16032
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study with pharmacodynamic evaluation of docetaxel-prednisone (DP) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line treatment in castration resistant prostate cancer (CRPC)
    Fontana, A.
    Galli, L.
    Derosa, L.
    Minuti, G.
    D'Arcangelo, M.
    Bursi, S.
    Landi, L.
    Bocci, G.
    Santini, D.
    Falcone, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 417 - 417
  • [2] DOCETAXEL-PREDNISONE (DP) PLUS METRONOMIC CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB (C) AS FIRST LINE TREATMENT IN CASTRATION RESISTANT PROSTATE CANCER (CRPC): PHASE II TRIAL WITH PHARMACODYNAMIC EVALUATION
    Fontana, A.
    Galli, L.
    Derosa, L.
    Minuti, G.
    D'Arcangelo, M.
    Fontana, E.
    Di Marsico, R.
    Venditti, O.
    Galluzzo, S.
    Landi, L.
    Bursi, S.
    Galli, C.
    Bona, E.
    Bocci, G.
    Antonuzzo, A.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2009, 20
  • [3] Results of a phase II study of picoplatin with docetaxel and prednisone in first-line treatment of castration-resistant prostate cancer (CRPC)
    De Jager, R. L.
    Roman, L.
    Lopatkin, N.
    Karlov, P.
    Breitz, H.
    Earhart, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for patients (pts) with castration-resistant prostate cancer (CRPC).
    Medioni, J.
    Ferrero, J.
    Deplanque, G.
    Maurina, T.
    Rodier, J. P.
    Raymond, E.
    Allyon, J.
    Renaux, S.
    Dufour-Lamartinie, J.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [5] Dose-finding and efficacy phase II study of inecalcitol, a new VDR agonist, in combination with docetaxel-prednisone regimen for castration-resistant prostate cancer (CRPC) patients (pts)
    Medioni, J.
    Deplanque, G.
    Ferrero, J.
    Maurina, T.
    Rodier, J. P.
    Raymond, E.
    Allyon, J.
    Renaux, S.
    Dufour-Lamartinie, J.
    Oudard, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [6] Phase II study of first-line sagopilone combined with prednisone in patients with metastatic castration-resistant prostate cancer (CRPC)
    Beer, T. M.
    Smith, D. C.
    Hussain, A.
    Alonso, M.
    Wang, J.
    Giurescu, M.
    Wang, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [7] DOCETAXEL (D) PLUS PREDNISONE (P) IN COMBINATION WITH METRONOMIC CYCLOPHOSPHAMIDE (CTX) AND CELECOXIB (C) AS FIRST LINE TREATMENT IN METASTATIC HORMONE REFRACTORY PROSTATE CANCER (MHRPC): A PHASE II CLINICAL TRIAL WITH PHARMACODYNAMIC EVALUATION
    Fontana, A.
    Bocci, G.
    D'Arcangelo, M.
    Galli, L.
    Bursi, S.
    Landi, L.
    Battaglini, P.
    Caponi, S.
    Del Tacca, M.
    Falcone, A.
    ANNALS OF ONCOLOGY, 2008, 19 : 198 - 199
  • [8] DOSE FINDING AND EFFICACY PHASE 2 STUDY OF INECALCITOL, A NEW VDR AGONIST, IN COMBINATION WITH DOCETAXEL-PREDNISONE REGIMEN FOR CASTRATION-RESISTANT PROSTATE CANCER (CRPC) PATIENTS (PTS)
    Medioni, Jacques
    Deplanque, Gael
    Maurina, Tristan
    Ferrero, Jean-Marc
    Rodier, Jean-Michel
    Raymond, Eric
    Ayllon, Jorge
    Renaux, Stephanie
    Dufour-Lamartinie, Jean-Francois
    Oudard, Stephane
    JOURNAL OF UROLOGY, 2011, 185 (04): : E285 - E286
  • [9] Phase I trial of metronomic cyclophosphamide (CTX) and lenalidomide (LEN) in patients with castration-resistant prostate cancer (CRPC).
    Wang, Jue
    McGuire, Timothy R.
    Schwarz, James K.
    Meza, Jane L.
    Talmadge, James E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [10] Docetaxel (D) plus prednisone (P) in combination with metronomic cyclophosphamide (CTX) and celecoxib (C) as first line chemotherapy in metastatic hormone refractory prostate cancer (HRPC): Phase II clinical trial with pharmacodynamic evaluation
    Fontana, A.
    Bocci, G.
    D'Arcangelo, M.
    Galli, L.
    Galli, C.
    Bursi, S.
    Landi, L.
    Antonuzzo, A.
    Del Tacca, M.
    Falcone, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345